Macro environment determinants affecting the availability of artemisinin-based combination therapies in Uganda

被引:0
|
作者
Oluka Nagitta, Pross [1 ]
Mkansi, Marcia [2 ]
机构
[1] Uganda Management Inst, Dept Econ & Managerial Sci, Kampala, Uganda
[2] Univ South Africa, Dept Operat Management, Pretoria, South Africa
关键词
Pharmaceutical supply chain; Political factors; Economic; Social-cultural; Legal; Technology; Developing countries; DEVELOPING-COUNTRIES; MALARIA; HEALTH; PROCUREMENT; MANAGEMENT; MEDICINE;
D O I
10.1108/IJPHM-09-2020-0074
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
PurposeArtemisinin-based combination therapies (ACTs) have been developed to treat uncomplicated malaria. However, scanty studies exist to inform the role of macro factors in explaining the nonavailability of ACT in developing countries. Therefore, this paper aims to evaluate the different macro-environment factors affecting the availability of ACTs in the public hospital setting. Design/methodology/approachThis study applied a quantitative methodological approach and structural equation modeling (SEM) to test hypotheses statistically. SEM examines linear causal relationships among variables while accounting for measurement error. Confirmatory factor analysis (CFA) was used to assess model reliability. CFA and SEM were used to determine the shared variance-covariance of variables, define the latent construct and provide a more precise way to account for the error variances associated with the variables, which, if untested, could lead to biased parameter estimates. This was guided by the data collected from 40 general public hospitals with 283 respondents. FindingsThis study's results support a model for promoting social-cultural, technological and legal factors. The availability of ACTs is significantly affected by legal factors. Improving legal aspects by a unit can enhance ACT availability by 0.59. Political factors scored the least, and they do not influence the availability of malaria drugs. Research limitations/implicationsThe design was quantitative and cross-sectional. Future research could be longitudinal with a mixed-method approach and consider other external stakeholders. Practical implicationsReducing the impact of the nonavailability of antimalarial drugs in general public hospitals requires a holistic concerted and coordinated supply chain approach that tackles the political, economic, social-cultural norms, technological and legal factors. Originality/valueThe authors develop and test a model using macro factors: political, economic, social, cultural, technological and legal factors. This model is relevant for many developing countries to supply chain coordination perpetually experiencing medicine shortages.
引用
收藏
页码:97 / 114
页数:18
相关论文
共 50 条
  • [41] Clinical pharmacology of artemisinin-based combination therapies (vol 47, pg 91, 2008)
    German, Polina I.
    Aweeka, Francesca T.
    CLINICAL PHARMACOKINETICS, 2008, 47 (03) : 152 - 152
  • [42] Policy brief on improving access to artemisinin-based combination therapies for malaria control in Ethiopia
    Kebede, Amha
    Woyessa, Adugna
    Urga, Kelbessa
    Messelle, Tsehaynesh
    Jima, Daddi
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2010, 26 (02) : 246 - 249
  • [43] Artemisinin-based combination therapies (ACTS): Best hope for malaria treatment but inaccessible to the needy!
    Mutabingwa, TK
    ACTA TROPICA, 2005, 95 (03) : 305 - 315
  • [44] Subsidizing artemisinin-based combination therapies: a preliminary investigation of the Affordable Medicines Facility - malaria
    Bate, Roger
    Hess, Kimberly
    Tren, Richard
    Mooney, Lorraine
    Cudjoe, Franklin
    Ayodele, Thompson
    Attaran, Amir
    RESEARCH AND REPORTS IN TROPICAL MEDICINE, 2012, 3 : 63 - 68
  • [45] Policy brief on improving access to artemisinin-based combination therapies for malaria in Burkina Faso
    Kouyate, Bocar
    Nana, Victor
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2010, 26 (02) : 233 - 236
  • [46] Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial (vol 395, pg 1345, 2020)
    van der Pluijm, R. W.
    Tripura, R.
    Hoglund, R. M.
    LANCET, 2020, 395 (10233): : 1344 - 1344
  • [47] Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda
    Bukirwa, Hasifa
    Yeka, Adoke
    Kamya, Moses R.
    Talisuna, Ambrose
    Banek, Kristin
    Bakyaita, Nathan
    Rwakimari, John Bosco
    Rosenthal, Philip J.
    Wabwire-Mangen, Fred
    Dorsey, Grant
    Staedke, Sarah G.
    PLOS CLINICAL TRIALS, 2006, 1 (01):
  • [48] Artemisinin-based combination therapy for knowlesi malaria
    Ramharter, Michael
    LANCET INFECTIOUS DISEASES, 2016, 16 (02): : 134 - 136
  • [49] Factors influencing patients' adherence to malaria artemisinin-based combination therapy in Kamuli District, Uganda
    Bawate, Charles
    Callender-Carter, Sylvia T.
    Guyah, Bernard
    Ouma, Collins
    MALARIA JOURNAL, 2024, 23 (01)
  • [50] Experiences of healthcare personnel on the efficacy of artemisinin-based combination therapy and malaria diagnosis in hospitals in Uganda
    Ocan, Moses
    Bakubi, Racheal
    Tayebwa, Mordecai
    Basemera, Joan
    Nsobya, Sam
    MALARIA JOURNAL, 2023, 22 (01)